Finding the right antibody for research is very important. Traditional lab methods test antibodies on plastic plates. This is called in vitro screening. However, the conditions in a lab dish are significantly different from those inside the body. An antibody that works on a plate may not work in a real biological environment. You need an antibody that can work well inside a living system, not just in a lab dish. Creative Biolabs is an expert in antibody discovery. As a leader in antibody screening and phage display, we offer a range of powerful solutions detailed on our Functional Phage Display Screening page. Among these advanced services, we are especially proud to offer in vivo phage display service. This technique enables us to identify the most effective antibodies by testing them directly within a living animal model. This process enables us to select antibodies that can travel through the body, reach their target, and perform their intended function correctly. It is an advanced and more effective method for discovering antibodies for your research.
Standard in vitro screening has helped scientists for years, but it has some important limitations:
Due to these issues, many antibodies that appear promising in the lab ultimately fail in later studies. Our in vivo antibody screening service helps you avoid these problems from the start.
Our in vivo phage display service is a complete solution designed to find the unique antibodies you need for tough research challenges. We take the search for antibodies out of the lab dish and into a more realistic environment. This service is perfect for projects that need antibodies with proven biological function.
To understand why in vivo phage display is such a significant technology, it is helpful to examine the history of antibody discovery. The journey has had several major steps.
This was the first major breakthrough. The process involves injecting an animal, usually a mouse, with a target antigen. The mouse's body then produces B cells that make antibodies against that target. Scientists collect these B cells from the mouse's spleen and fuse them with long-lasting cancer cells (myeloma cells). This creates a hybrid cell, known as a hybridoma. These hybridomas can be grown in the lab to produce a large amount of a single, very specific antibody, called a monoclonal antibody. However, this method produces mouse antibodies. When mouse antibodies are used in humans, the human immune system can perceive them as foreign and respond by attacking them. This is called the HAMA (Human Anti-Mouse Antibody) response, which limits their use as a medicine.
Another powerful way to solve the problem with mouse antibodies is to use transgenic mouse technology. Scientists have created mice with human antibody genes integrated into their DNA. These mice are a major step forward in antibody discovery. The process is very direct. First, the transgenic mouse is immunized with the target antigen. Because these mice have human genes, their immune systems produce fully human antibodies in response. Next, scientists harvest the antibody-producing spleen cells from the mouse. These cells are then fused with tumor cells to create hybridomas, just like in the traditional method. The great advantage is that these hybridomas produce a stable supply of fully human monoclonal antibodies from the very beginning. This advanced method avoids the need for extra engineering steps like humanization.
The next big step was the invention of display technologies. Phage display is the most powerful and popular of these methods. It allows us to create huge libraries of human antibody fragments. We can then search these libraries to find antibodies for almost any target. This approach is faster and more flexible than hybridoma technology. The offered in vivo phage display service is the most advanced form of this powerful technology.
Fig.1 Key technologies for generating monoclonal antibodies.1
Our method uses a living animal as the environment to find the best antibodies. The process is direct and very effective.
Fig.2 The in vivo phage display selection process.1
At Creative Biolabs, we provide a complete service to support your research goals.
In vivo phage display is useful for many difficult research challenges.
This is a very powerful tool for tumor-homing antibody discovery. We can find antibodies that can get inside a tumor and bind to cancer cells. For example, this method has been used to find a llama VHH antibody that targets blood vessels in brain tumors (glioma).
The brain is protected by a strong barrier called the BBB. It is very hard for most molecules to cross it. Our service can find rare antibodies that are able to pass through the BBB and enter the brain. This has been used to discover both scFv and sdAb antibodies that can successfully target the brain.
We can use in vivo panning to find new targets in diseases like atherosclerosis. For example, scientists used this technique to identify scFv antibodies that bind to atherosclerotic plaques. This work helped show that galectin-3 is an important biomarker for the disease.
In vivo phage display is a powerful and modern way to find better antibodies for your research. The expert team at Creative Biolabs has the skill and experience to make your project a success. We are ready to help you discover the antibodies you need to make the next big breakthrough. to speak with our scientists. We look forward to helping you reach your goals.
Leading research increasingly validates in vivo phage display as a premier strategy for discovering antibody fragments with superior targeting and drug delivery properties. This advanced methodology has been successfully employed across various animal models to isolate high-affinity binders for challenging therapeutic areas. For example, studies in rabbit models of atherosclerosis have identified specific scFv fragments targeting key biomarkers like Carbonic anhydrase II and Galectin-3. In cancer research, in vivo screening has led to the discovery of a llama VHH antibody targeting Dynactin-1-p150Glued in glioma mouse models and unique scFv fragments from screenings in cancer patients. Furthermore, the power of this technique in neuroscience is highlighted by the identification of scFv and sdAb clones, such as the RG3 sdAb, capable of efficiently crossing the blood-brain barrier (BBB) in rodent models. Other successes include the isolation of scFvs specifically targeting pancreatic islets. Collectively, these findings demonstrate the unique advantage of in vivo phage display in selecting for antibodies that not only bind to their target in a native physiological context but also possess desirable pharmacokinetic properties, making it an invaluable tool for developing next-generation biologics.
Fig.3 Successful antibody discoveries using in vivo phage display.1
Reference:
Please kindly note that our services can only be used to support research purposes (Not for clinical use).
Creative Biolabs is a globally recognized phage company. Creative Biolabs is committed to providing researchers with the most reliable service and the most competitive price.
